Gilead Sciences, Inc. (GILD) Shares Bought by Capital City Trust Co. FL

Capital City Trust Co. FL grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,262 shares of the biopharmaceutical company’s stock after buying an additional 418 shares during the period. Capital City Trust Co. FL’s holdings in Gilead Sciences were worth $302,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. boosted its holdings in shares of Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares in the last quarter. Penserra Capital Management LLC boosted its holdings in shares of Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares in the last quarter. Webster Bank N. A. boosted its holdings in shares of Gilead Sciences by 51.7% during the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 624 shares in the last quarter. Finally, American Beacon Advisors Inc. bought a new position in shares of Gilead Sciences during the 1st quarter worth approximately $143,000. Hedge funds and other institutional investors own 74.05% of the company’s stock.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares in the company, valued at $227,197,799. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Robin L. Washington sold 51,820 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The disclosure for this sale can be found here. In the last quarter, insiders have sold 466,819 shares of company stock valued at $36,740,240. 1.30% of the stock is owned by company insiders.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 82.36 on Friday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The stock has a market cap of $107.56 billion, a price-to-earnings ratio of 8.95 and a beta of 1.19. The company has a 50-day moving average price of $77.16 and a 200 day moving average price of $70.20.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.08 earnings per share. Equities research analysts expect that Gilead Sciences, Inc. will post $8.75 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

WARNING: “Gilead Sciences, Inc. (GILD) Shares Bought by Capital City Trust Co. FL” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/09/16/gilead-sciences-inc-gild-shares-bought-by-capital-city-trust-co-fl.html.

A number of research firms have issued reports on GILD. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Deutsche Bank AG restated a “buy” rating and set a $81.00 price target (up from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Royal Bank Of Canada began coverage on Gilead Sciences in a report on Thursday. They set an “outperform” rating and a $94.00 price target on the stock. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. Finally, TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Eleven investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and an average target price of $83.79.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply